GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemia.

"Declarations Ethics approval and consent to participateAll animal experiments were approved by The Animal Care & Welfare Committee of Guangzhou Women and Children’s Medical Center, Guangzhou Medical University. Patient samples preparation was approved by the Institutional Review Board of the Guangzhou Women and Children’s Medical Center. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This study was supported by grants from the National Natural Science Foundation of China (Nos. 82100178, 82200118, 82170145), NSFC Incubation Project of Guangdong Provincial People’s Hospital (KY0120220038), Guangdong Basic and Applied Basic Research Foundation (2021A1515110860), Guangzhou Health Technology Project (20221A011037), Basic and Applied Basic Research Foundation of Guangzhou Municipal Science and Technology Project (202201010999), Research Foundation of Guangzhou Women and Children’s Medical Center for Clinical Doctor (1600077), State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute (KF2107), Shanghai Municipal Commission of Health and Family Planning (NO. ZY (2021-2023)-0208)."